GeneDx Holdings Corp. (WGS), a healthcare company, on Monday reported net loss in the fourth quarter despite higher revenue compared with the previous year.
For the fourth quarter, net loss came in at $17.67 million from $5.44 million in the previous year.
Loss per share were $0.61 versus $0.18 last year.
Adjusted net income decreased to $4.40 million from $17.45 million in the prior year.
Adjusted earnings per share were $0.14 versus $0.59 last year.
Loss from operations came in at $14.24 million compared with profit of $8.81 million from
Revenue increased to $120.99 million from $95.64 million in the previous year.
Further, the company reaffirms full-year 2026 revenue guidance of $540 million to $555 million and adjusted net income to be positive for the year.
In the pre-market trading, GeneDx is 3.58% higher at $85 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.